Exalenz files for FDA approval of diagnostic device

04/2/2008 | Globes (Israel)

Exalenz Bioscience Ltd. is seeking FDA approval to market its BreathID diagnostic system, designed to rapidly spot damage to the liver from cirrhosis and hepatic disorder. The noninvasive device reached 90% accuracy compared with biopsies, the company said.

View Full Article in:

Globes (Israel)

Published in Brief:

SmartBrief Job Listings for Health Care